Trial intelligence / Profile preview

PRIDE in newly diagnosed IDH-wildtype, MGMT-unmethylated glioblastoma

2024-514865-20-00Phase 2Authorised

Sponsor: University Hospital Tübingen
Start: Apr 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, open-label, single-arm trial of bevacizumab in glioblastoma (GBM), sponsored by University Hospital Tübingen. Primary endpoint: Overall survival. Planned start Apr 2024; status: authorised.

Drugs

bevacizumab

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on 2024-514865-20-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514865-20-00.